Incyte (INCY) Stock Price, Quote, News & History | Benzinga

Incyte Corp (INCY) Stock Price, Quote, News & History

INCYNASDAQ

Trade with Public

Trade with Public

$120.36

-0.41-0.34%

Last update: Aug 13, 12:39 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$122.23

Close

-

Volume / Avg.

268.52K / 1.87M

Day Range

$119.71 - $122.23

52 Wk Range

79.33 - 132.60

Market Cap

$24.40B

P/E Ratio

15.38

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

8.62%

Days to Cover

4.8

Recent Incyte Corp News

Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65, BTIG boosted SNOW's target to $340, and JP Morgan upgraded LYB to Overweight.

Avi Kapoor

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales growth, pipeline progress, and business development. Analysts maintain buy ratings with price target increases.

Avi Kapoor

Top 3 Health Care Stocks That May Implode This Month

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences

Avi Kapoor

Incyte Says It's No Longer A One-Drug Story

Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.

Vandana Singh

ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’

ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to close at $593.87 on Monday.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.98B

Investing Cash Flow (TTM)

-224.83M

Financing Cash Flow (TTM)

275.24M

Free Cash Flow (TTM)

1.89B

Capital Expenditure (TTM)

-89.24M

Net Change in Cash (TTM)

2.03B

Analyst Trends and Forecast

2

Apr

2

1

May

3

2

Jun

5

4

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.6

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$19.98B

PE Ratio (TTM)

15.38

PE Ratio (FWD)

38.76

PEG Ratio (TTM)

28.77

PS Ratio (TTM)

4.26

PB Ratio (TTM)

3.86

Earnings Yield % (TTM)

6.50%

Earnings Yield % (FWD)

2.58%

EV / EBITDA (TTM)

9.66

Price / EBITDA (TTM)

11.99

Price / Free Cash Flow (TTM)

13.11

Book Value / Share

$31.30

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$4.64M

Total Cash

$3.98B

Debt to Equity

0.01

Issuance of Debt (TTM)

-$4.64M

Repayment of Debt (TTM)

-$4.64M

Key Statistics

Open

$122.23

Close

-

Volume / Avg.

268.52K / 1.87M

Day Range

$119.71 - $122.23

52 Wk Range

79.33 - 132.60

Market Cap

$24.40B

P/E Ratio

15.38

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

8.62%

Days to Cover

4.8

About

Sector

Health Care

Industry

Biotechnology

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Incyte (INCY) stock?

A

You can purchase shares of Incyte (NASDAQ:INCY) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Incyte (INCY) competitors?

A

Other companies in Incyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Incyte (INCY) stock?

A

Incyte has a consensus price target of $109.82.

Q

What is the current price for Incyte (INCY)?

A

The stock price for Incyte (NASDAQ: INCY) is $120.365 last updated August 13, 2026 at 12:39 PM EDT.

Q

Does Incyte (INCY) pay a dividend?

A

There are no upcoming dividends for Incyte.

Q

When is Incyte (NASDAQ:INCY) reporting earnings?

A

Incyte does not have any upcoming earnings scheduled.

Q

Is Incyte (INCY) going to split?

A

There is no upcoming split for Incyte.

Q

What sector and industry does Incyte (INCY) operate in?

A

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.